Lea Nussbaum is a Scientific Coordinator at the National Center for Tumor Diseases (NCT) Heidelberg since July 2022. Prior to this role, Nussbaum was a Postdoctoral Researcher at the University of Oxford from August 2016 to June 2022, where research focused on CD1a-restricted regulatory T cell responses in health and psoriasis. Nussbaum held various research assistant and internship positions at Heidelberg University, contributing to projects on HBV and HDV, genome editing with CRISPR, and gene expression analysis in cancer. Nussbaum earned a DPhil in Infection, Immunology and Translational Medicine from the University of Oxford and holds Master's and Bachelor's degrees in Molecular Biotechnology from Heidelberg University.
National Center for Tumor Diseases (NCT) Heidelberg
The National Center for Tumor Diseases (NCT) Heidelberg is a joint institution of the German Cancer Research Center (DKFZ), Heidelberg University Hospital and German Cancer Aid. The NCT's goal is to link promising approaches from cancer research with patient care from diagnosis to treatment, aftercare and prevention. The interdisciplinary tumor outpatient clinic is the central element of the NCT. Here the patients benefit from an individual treatment plan prepared in a timely manner in interdisciplinary expert rounds, the so-called tumor boards. Participation in clinical studies provides access to innovative therapies. The NCT thereby acts as a pioneering platform that translates novel research results from the laboratory into clinical practice. The NCT cooperates with self-help groups and supports them in their work. Since 2015, a second site for the NCT beside Heidelberg has been under development in Dresden.